Literature DB >> 21677406

Identification of possible genetic polymorphisms involved in cancer cachexia: a systematic review.

Benjamin H L Tan1, James A Ross, Stein Kaasa, Frank Skorpen, Kenneth C H Fearon.   

Abstract

Cancer cachexia is a polygenic and complex syndrome. Genetic variations in regulation of the inflammatory response, muscle and fat metabolic pathways, and pathways in appetite regulation are likely to contribute to the susceptibility or resistance to developing cancer cachexia. A systematic search of Medline and EmBase databases, covering 1986-2008 was performed for potential candidate genes/genetic polymorphisms relating to cancer cachexia. Related genes were then identified using pathway functional analysis software. All candidate genes were reviewed for functional polymorphisms or clinically significant polymorphisms associated with cachexia using the OMIM and GeneRIF databases. Genes with variants which had functional or clinical associations with cachexia and replicated in at least one study were entered into pathway analysis software to reveal possible network associations between genes. A total of 184 polymorphisms with functional or clinical relevance to cancer cachexia were identified in 92 candidate genes. Of these, 42 polymorphisms (in 33 genes) were replicated in more than one study with 13 polymorphisms found to influence two or more hallmarks of cachexia (i.e. inflammation, loss of fat mass and/or lean mass and reduced survival). Thirty-three genes were found to be significantly interconnected in two major networks with four genes (ADIPOQ, IL6, NFKB1 and TLR4) interlinking both networks. Selection of candidate genes and polymorphisms is a key element of multigene study design. The present study provides an initial framework to select genes/polymorphisms for further study in cancer cachexia, and to develop their potential as susceptibility biomarkers of developing cachexia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21677406     DOI: 10.1007/s12041-011-0027-4

Source DB:  PubMed          Journal:  J Genet        ISSN: 0022-1333            Impact factor:   1.166


  100 in total

Review 1.  Metallothionein in human disease.

Authors:  C O Simpkins
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2000-03       Impact factor: 1.770

2.  Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population.

Authors:  Haruhiko Osawa; Yasuharu Tabara; Ryuichi Kawamoto; Jun Ohashi; Masaaki Ochi; Hiroshi Onuma; Wataru Nishida; Kazuya Yamada; Jun Nakura; Katsuhiko Kohara; Tetsuro Miki; Hideichi Makino
Journal:  Diabetes Care       Date:  2007-03-23       Impact factor: 19.112

3.  Association of TNF haplotypes with asthma, serum IgE levels, and correlation with serum TNF-alpha levels.

Authors:  Shilpy Sharma; Amit Sharma; Sarvesh Kumar; Surendra K Sharma; Balaram Ghosh
Journal:  Am J Respir Cell Mol Biol       Date:  2006-05-25       Impact factor: 6.914

4.  Absence of the wild-type allele (192 base pairs) of a polymorphism in the promoter region of the IGF-I gene but not a polymorphism in the insulin gene variable number of tandem repeat locus is associated with accelerated weight gain in infancy.

Authors:  Eva Landmann; Frank Geller; Jutta Schilling; Silvia Rudloff; Eleonore Foeller-Gaudier; Ludwig Gortner
Journal:  Pediatrics       Date:  2006-12       Impact factor: 7.124

Review 5.  Metabolism of lipids in human white adipocyte.

Authors:  V Large; O Peroni; D Letexier; H Ray; M Beylot
Journal:  Diabetes Metab       Date:  2004-09       Impact factor: 6.041

6.  Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway.

Authors:  Nirupama Silswal; Anil K Singh; Battu Aruna; Sangita Mukhopadhyay; Sudip Ghosh; Nasreen Z Ehtesham
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

7.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

8.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.

Authors:  A G Wilson; J A Symons; T L McDowell; H O McDevitt; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

9.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

Review 10.  Cytokine receptor signalling.

Authors:  J N Ihle
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

View more
  19 in total

Review 1.  Energy metabolism in cachexia.

Authors:  Maria Rohm; Anja Zeigerer; Juliano Machado; Stephan Herzig
Journal:  EMBO Rep       Date:  2019-03-19       Impact factor: 8.807

2.  Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.

Authors:  A Miller; L McLeod; S Alhayyani; A Szczepny; D N Watkins; W Chen; P Enriori; W Ferlin; S Ruwanpura; B J Jenkins
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

3.  C-reactive protein levels and vitamin d receptor polymorphisms as markers in predicting cachectic syndrome in cancer patients.

Authors:  Tiziana Punzi; Ariele Fabris; Gabriele Morucci; Paolo Biagioni; Massimo Gulisano; Marco Ruggiero; Stefania Pacini
Journal:  Mol Diagn Ther       Date:  2012-04-01       Impact factor: 4.074

Review 4.  Genetic basis of interindividual susceptibility to cancer cachexia: selection of potential candidate gene polymorphisms for association studies.

Authors:  N Johns; B H Tan; M MacMillan; T S Solheim; J A Ross; V E Baracos; S Damaraju; K C H Fearon
Journal:  J Genet       Date:  2014-12       Impact factor: 1.166

5.  Hyperlipidaemia in trypanosomiasis of naturally infected horses: possible cachexia-anorexia syndrome?

Authors:  Muthusamy Ranjithkumar; Tauseef Ahmed Malik; Anju Saxena; Ananya Dan; Pillanatham Civalingam Sakthivel; Sahadeb Dey
Journal:  Trop Anim Health Prod       Date:  2012-07-27       Impact factor: 1.559

Review 6.  Protein anabolic resistance in cancer: does it really exist?

Authors:  Mariëlle P K J Engelen; Barbara S van der Meij; Nicolaas E P Deutz
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2016-01       Impact factor: 4.294

Review 7.  The diverse and complex roles of NF-κB subunits in cancer.

Authors:  Neil D Perkins
Journal:  Nat Rev Cancer       Date:  2012-01-19       Impact factor: 60.716

8.  P-selectin genotype is associated with the development of cancer cachexia.

Authors:  Benjamin H L Tan; Torill Fladvad; Theodore P Braun; Antonio Vigano; Florian Strasser; D A Christopher Deans; Richard J E Skipworth; Tora S Solheim; Sambasivarao Damaraju; James A Ross; Stein Kaasa; Daniel L Marks; Vickie E Baracos; Frank Skorpen; Kenneth C H Fearon
Journal:  EMBO Mol Med       Date:  2012-04-04       Impact factor: 12.137

9.  Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients.

Authors:  Nathan A Stephens; Richard J E Skipworth; Iain J Gallagher; Carolyn A Greig; Denis C Guttridge; James A Ross; Kenneth C H Fearon
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-03-31       Impact factor: 12.910

10.  AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients.

Authors:  Abolfazl Avan; Amir Avan; Tessa Y S Le Large; Andrea Mambrini; Niccola Funel; Mina Maftouh; Majid Ghayour-Mobarhan; Maurizio Cantore; Ugo Boggi; Godefridus J Peters; Paola Pacetti; Elisa Giovannetti
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.